Astrazeneca (AZN) EBT (2009 - 2026)

Astrazeneca (AZN) has reported EBT for 18 consecutive years, with $3.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 15.05% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $12.9 billion (up 38.96% YoY), while the FY2025 annual figure was $12.4 billion, up 42.7% from the prior year.
• EBT came in at $3.9 billion for Q1 2026 at Astrazeneca, up from $2.6 billion in the prior quarter.
• The five-year high for EBT was $3.9 billion in Q1 2026, with the low at $247.0 million in Q2 2022.
• Average EBT over 5 years is $2.0 billion, with a median of $2.1 billion recorded in 2023.
• Across the five-year window, EBT tumbled 67.67% in 2022 and surged 745.34% in 2023, its largest moves.
• Year by year, EBT stood at $778.0 million in 2022, then gained by 15.3% to $897.0 million in 2023, then soared by 85.73% to $1.7 billion in 2024, then surged by 57.8% to $2.6 billion in 2025, then soared by 48.88% to $3.9 billion in 2026.
• According to Business Quant data, EBT over the past three periods registered $3.9 billion, $2.6 billion, and $3.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.